Blog

Investor Spotlight: Forbion Capital

Investor Spotlight: Forbion Capital
The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities. On September 6th, Sander Van Deventer, MD Ph.D., Managing Partner and Marco Boorsma, Ph.D., Partner of the Forbion Capital Partners team will be in attendance to give an overview presentation about their company's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online. *Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due August 10, 2017. Apply Here. Program Overview: Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages over €700M across six closed-end funds, including its 0M+ FCFIII fund, launched in 2016, for which Forbion is actively looking for new exciting opportunities across: Therapeutics Drug Development Medical Devices Diagnostics Forbion Capital Partners currently has ~27 active investments (globally) and invests in early & late stage ventures in Europe, US and Canada. Besides financial support, Forbion also helps companies to bridge research and development through the team’s expertise in drug development and company building. Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Forbion Capital Partners will provide an intimate forum to discuss your company. Agenda: 10:30 AM | Registration and Networking 11:00 AM | Presentation and Q&A 12:00 PM | Networking and Lunch 12:30 PM – 5:00 PM | One-on-one Meetings* *Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on August 10, 2017. Fees: | General Public Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 5th (or sold out). Location: JLABS @ Toronto 661 University Ave, Suite 1300 Toronto, Ontario Forbion Capital Representatives: Sander van Deventer | Managing Partner, Forbion Capital Sander van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a Managing Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), Uniqure (Amsterdam, The Netherlands), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada). He was trained as an internist and board certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. He has authored more than 500 peer review scientific papers, and supervised more than 40 PhD students. Connect with Sander:   Marco Boorsma | Partner, Forbion Capital Marco has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. He serves on the Board of RSPR Pharma and Prexton Therapeutics, and is Observer to the Board of Exosome Diagnostics and Oxyrane. He was instrumental in the start-up of Dezima Pharma and subsequently served on its Board. Dezima was sold to Amgen for up to USD1.5Bn in 2015. Marco also served on the Board of Akarna Therapeutics, which was sold in 2016 to Allergan for up to USD 1Bn after 6 months of investing. Before joining Forbion Marco was Business Development Director at DSM Pharmaceutical Products, responsible for out-licensing of biomanufacturing technologies and securing and managing contract manufacturing projects. Prior to that Marco was a project manager and scientist responsible for process development and cGMP manufacturing of biopharmaceuticals. While at Cytos Biotechnology (Switzerland) Marco developed manufacturing processes for high-value biosimilar proteins. After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, Switzerland for his work on virus-based gene expression systems, partly in collaboration with the Laboratory of Molecular Biology of the Medical Research Counsil in Cambridge, UK. Connect with Marco:  

at SMARTWEEK 2014 TORONTO
DAY 1: Industry Day – MaRS Discovery District: 101 College Street, Toronto, ON M5S 2E4
Toronto, Canada

no comment

Leave a Reply